Eble M J, Staehler G, Wannenmacher M
Radiologische Klinik, Ruprecht-Karls-Universität Heidelberg.
Strahlenther Onkol. 1998 Jan;174(1):30-6. doi: 10.1007/BF03038225.
Renal cell carcinomas are relatively radioresistant. After macroscopically incomplete tumor resection conventional external beam radiotherapy is dose-limited and additional systemic treatment with chemotherapy ineffective to achieve local control. In a pilot study the role of intraoperative radiotherapy in the treatment of locally advanced or recurrent renal cell carcinomas was analysed.
From January 1992 to July 1994 11 patients with a primary (n = 3) or recurrent renal cell carcinoma had IORT. One patient had complete resection and in 3 respectively 7 patients microscopically or macroscopically residual disease was left. Using 6 to 10 MeV, a single dose of 15 to 20 Gy was delivered to the fossa renalis and the corresponding paraaortic area. Based on three-dimensional treatment planning, additional external beam radiotherapy was given 3 to 4 weeks later (40 Gy, 2 Gy SD, 23 MV).
After a mean follow-up of 24.3 months 5 patients had died of distant metastases (lung, liver, bone, mediastinum) with a mean survival time of 11.5 months. Mean disease-free interval was 6.4 months. One patient suffered from a second malignancy. Two patients are alive with distant metastases. Local tumor control in the entire group was 100%. The calculated 4-year overall and disease-free survival was 47% and 34%. The postoperative course was affected in 3 patients (abscess n = 1, short dehiscence of the abdominal wound n = 2). The gastrointestinal toxicity during external beam radiotherapy was low. No IORT-specific late adverse effects were observed.
After incomplete tumor resection local tumor control with minimal therapy related side effects could be achieved using intraoperative radiotherapy. With IORT the dose limitation in the radiotherapy of renal cell carcinoma could be overcome. The high distant metastases rate relativized overall prognosis. The low morbidity rate justifies further evaluation of this technique.
肾细胞癌相对对放疗不敏感。在肉眼下肿瘤切除不完全后,传统外照射放疗的剂量受到限制,而额外的化疗全身治疗对实现局部控制无效。在一项前瞻性研究中,分析了术中放疗在局部晚期或复发性肾细胞癌治疗中的作用。
从1992年1月至1994年7月,11例原发性(n = 3)或复发性肾细胞癌患者接受了术中放疗。1例患者肿瘤完全切除,3例和7例患者分别有镜下或肉眼可见的残留病灶。使用6至10兆电子伏特,单次剂量15至20戈瑞照射肾窝及相应的腹主动脉旁区域。基于三维治疗计划,3至4周后给予额外的外照射放疗(40戈瑞,每日2戈瑞,23兆伏)。
平均随访24.3个月后,5例患者死于远处转移(肺、肝、骨、纵隔),平均生存时间为11.5个月。平均无病间期为6.4个月。1例患者发生第二种恶性肿瘤。2例患者有远处转移存活。整个组的局部肿瘤控制率为100%。计算得出的4年总生存率和无病生存率分别为47%和34%。3例患者术后病程受到影响(1例脓肿,2例腹部伤口短期裂开)。外照射放疗期间胃肠道毒性较低。未观察到术中放疗特有的晚期不良反应。
在肿瘤切除不完全后,使用术中放疗可实现局部肿瘤控制,且治疗相关副作用最小。通过术中放疗可克服肾细胞癌放疗中的剂量限制。远处转移率高使总体预后相对化。低发病率证明对该技术进行进一步评估是合理的。